The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and/or into the wound of a patient.

An adhesive material for medical use comprising gelatin and a non-toxic cross-linking material such as transglutaminase. An optional embodiment of the invention includes dressings in which a layer of a transglutaminase is sandwiched between a first and second layer of gelatin. The hemostatic products are useful for the treatment of wounded tissue.

Adhesive compositions are described which include one or more gelling agents in combination with one or more non-gelling disintegrants. The adhesive compositions exhibit relatively high fluid handling capacities and static absorption properties, thus enabling their use in a wide range of medical applications. Various adhesive articles such as dressings and related methods of use are also described which utilize the adhesive compositions. In preferred embodiments the adhesive component is an acrylic adhesive, the gelling agent is selected from the group consisting of (i) carboxymethyl cellulose, (ii) superabsorbent polymer, and (iii) combinations of (i) and (ii), and the non-gelling disintegrant is selected from the group consisting of (i) fully pregelatinized potato starch, (ii) microcrystalline celluloseand (iii) combinations of any of (i)-(ii).

The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (TA). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site.

A discontinuous silicone article is disclosed that includes a plurality of strands of radiation cured silicone gel arranged to form a net-like structure with openings between strands. The silicone gel provides adhesion to a surface, such as skin, and the openings provide for moisture transmission away from the surface. The discontinuous silicone article comprises at least one adhesive polymer strand and a plurality of joining strands. The adhesive polymer strands comprise a radiation cured silicone gel and each polymer strand repeatedly contacts an adjacent joining strand at bond regions.

The inventive composition first is highly viscous, remaining in place when administered to a patient. Then it decreases in viscosity and liquefies, facilitating easy removal, after a period of time ranging from minutes to weeks, such as after a change in temperature or other trigger; or after another component is added to cause liquefaction. Such compositions have many different medical uses, optionally with a treating agent contained in, or held in place by, the composition, such as, without limitation, prevention or reduction in scarring or adhesions after surgery involving the uterus or other body or organ cavities or other sites, by keeping raw areas of the tissue or tissue walls separated from each other during healing; delivery or retention of treating agents in body or organ cavities or other sites of administration; protection of wounds, burns, and other injuries; and holding tissue grafts in place. Even cosmetic uses are available.

Medical dressings include a non-woven polymeric nanofiber mat embedded within a chitosan hydrogel matrix. The dressings may be obtained by electro spinning of polymeric nanofibers and thereafter incorporating a chitosan hydrogel into interstices of the mat by vacuum or positive pressure assistance. The resulting medical dressings may be optically transparent (e.g., at least about 50% up to about 95% light transmittance), flexible, and mechanically robust. The dressings may also incorporate self-adhesion promoters to allow self-adhesion to biological tissue, e.g., ocular surfaces, and/or therapeutic agents which are capable of delivering therapeutics (e.g. stem cells, drugs and the like) to the tissue surface. The dressings are especially useful as ocular bandages for the treatment and repair of ocular wounds.

Film forming gel compositions, useful in creating conformable and flexible gel bandages, can be formulate from a film forming polymer, a tackifier, and a volatile solvent. The film forming gels can also include antiseptics, cationic polymer coagulants, fillers, and other additives. The gel compositions form relatively thick films when dried on tissue, and can exhibit enhanced breathability to promote wound healing.

Adhesive articles include a substrate; and a hot melt processable pressure sensitive adhesive on the substrate. The hot melt processable pressure sensitive adhesive is a (meth)acrylate-based copolymer that is the reaction product of a reaction mixture that is free of acidic or basic monomers, and includes an alkyl (meth)acrylate, a hydroxyl-functional (meth)acrylate, and a photocrosslinker. The (meth)acrylate-based polymer is prepared in a thermoplastic package.

The present invention is directed to hemostatic material containing compacted ORC powder comprising particles having an average aspect ratio from about 1 to about 18, wherein said compacted ORC powder have preferably been processed in a compaction device, such as a ball milled ORC powder. The present invention further relates to methods of making the hemostatic material and a method of treating a wound by applying the hemostatic powder onto and/or into the wound of a patient.